Who's who

3 Houston innovators to know this week

Here's who you need to know this week in Houston innovation. Courtesy photos

This group of innovators to know this week are passionate people. From starting companies to making acquisitions, here's what they are up to and why you need to know their names.

Kelly McCormick, director of RED Labs

Photo courtesy of UH

Kelly McCormick is in the business of making University of Houston's entrepreneurs' dreams into realities. The RED Labs director wrote a guest article for InnovationMap about side hustles — what they are and how to make them worth their while.

"A side hustle has a science to it, and more importantly, it has an art," she writes. Read her full article here.

Randa Duncan Williams, chairman of Enterprise Products Partners LP

Photo courtesy of Texas Monthly

For the second time in three years, Texas Monthly has a new owner. But if Randa Duncan Williams — energy exec and heiress worth over $6 billion — has anything to say about it, she'll be the last new owner of the magazine. Duncan Williams — who acquired the magazine by way of a privately held company, Enterprise Products Company, that's a subsidiary of Enterprise Products Partners, the company her late father founded — says she wants to own the magazine "forever." Read the full story here.

Cody Gremminger, system engineer at Cyber One Solutions

Cody Gremminger

Photo courtesy of Cyber One Solutions

Cody Gremminger is running a booming tech services business with his fiance, Brian Carrico. The company is called Cyber One Solutions and provides management, service and IT support services to the greater Houston area with satellite offices in Austin, Dallas, Lufkin, Brenham, and Beaumont.

While business couldn't be better, the entrepreneur wants to make sure Houston takes this month to remember the losses and challenges that the LGBT community has endured to get where it is today. Read the full story here.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted